- The clinical trials for Dovato (a combination of dolutegravir and 3TC) for the initial treatment of HIV or for a change to a simpler regimen have found this ...
- The pharmaceutical company ViiV Healthcare has been the leader in developing potent dual-drug HIV regimens, such as the following: . Juluca – a pill ...
- Dolutegravir belongs to a class of anti-HIV drugs called integrase inhibitors. In Canada and other high-income countries, dolutegravir is sold in the following ...
- CATIE NewsScientists conducted a randomized study of ketamine and mindfulness. Results appear promising as some people were able to stop using cocaine. More research lies ...
- CATIE NewsScientists in B.C. mapped the flow of patients from hepatitis C diagnosis to cure. At each stage of the cascade, some patients did not progress to the next step ...
- CATIE NewsResearchers evaluated an online testing service for sexually transmitted infections. The B.C. program offers direct access to testing through online lab ...
- CATIE NewsPost-exposure prophylaxis (PEP) can prevent HIV if initiated within 72 hours. Some Toronto clinicians prescribed PEP in advance to reduce delays in initiation. ...
- CATIE NewsResearchers compared the health of HIV-positive and HIV-negative women. Women with HIV were nearly 60% more likely to have another health condition . ...
- WebinarThe integration of hepatitis C care within broader harm reduction or related HIV service models could remove some of the barriers to access and engagement. This ...
- CATIE NewsFrailty can sometimes occur early in HIV-positive people. In a recent study, frailty was linked to an increased risk for heart disease and diabetes. Research ...
- CATIE News80% of people with HIV used cannabis at least once weekly, mostly through smoking. The top reported reason was pleasure, followed by stress and anxiety ...